查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1702363

全球癌症診斷市場 - 2025-2033

Global Cancer Diagnostics Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球癌症診斷市場規模達到 217.1 億美元，預計到 2033 年將達到 426.4 億美元，在 2025-2033 年預測期內的複合年成長率為 8.7%。

全球癌症診斷市場涵蓋專注於檢測和診斷各種類型癌症（尤其是早期癌症）的醫療設備、工具、技術和服務的行業。該市場包括廣泛的診斷解決方案，例如影像方法（例如，MRI、CT 掃描、PET 掃描）、分子和基因測試（例如，下一代定序、液體活體組織切片）、病理學測試和有助於識別癌症相關生物標記的篩檢技術。

這些診斷工具的主要目的是提供準確、及時的癌症檢測，從而提供更有效、個人化的治療方案，並最終改善患者的治療效果和存活率。癌症盛行率的不斷上升、診斷技術的不斷進步以及對早期檢測和個人化癌症治療的需求不斷增加推動了市場的發展。

市場動態：

駕駛員和約束裝置

癌症發生率和盛行率上升

癌症發病率和盛行率的上升極大地推動了癌症診斷市場的成長，預計在預測期內將繼續推動市場的發展。例如，根據2022年Globocon的資料，男性癌症發生率為1,030萬，女性為970萬。 2025年，預計男性癌症發生人數將達1,250萬，女性癌症發生人數將達1,160萬。發病率的不斷上升凸顯了對可獲得且經濟高效的癌症診斷解決方案的迫切需求。

全球人口老化導致癌症風險增加，因為老年人更容易罹患癌症。這種人口結構的變化導致癌症病例增加，凸顯了對能夠在早期發現癌症的診斷測試的需求日益成長，最終改善治療效果。

因此，癌症病例的增加直接推動了對癌症診斷的需求，從而帶動相關產品和服務的市場不斷成長。這包括對於識別和監測不同類型癌症至關重要的診斷測試、影像系統和實驗室服務。這些趨勢迫切需要先進的診斷技術，推動市場成長，並強調解決全球癌症治療差距的重要性。

診斷程序和設備成本高昂

診斷程序和設備的高成本是癌症診斷市場成長的重大障礙。一些先進的診斷工具對於早期和準確地發現癌症至關重要，但實施這些工具的高昂費用可能會帶來重大挑戰。這些工具，例如次世代定序 (NGS)、液體活體組織切片和高解析度成像系統，具有直接和間接成本，限制了它們的可及性和廣泛使用。

據研究人員稱，2021 年初步癌症篩檢的年度費用估計為 430 億美元，低於美國癌症確診後前 12 個月的年度治療費用。他們強調，了解癌症篩檢成本及其潛在因素對於制定政策決策和指導旨在改善獲得推薦癌症篩檢服務的計劃至關重要。

先進的診斷技術需要大量的前期投資。例如，NGS 系統的成本可能高達數十萬美元，而 PET/CT 掃描儀或 MRI 機器等高解析度成像機器的成本可能高達數百萬美元。購買這些機器的價格是一個主要障礙，特別是對於中低收入國家的小型醫院、診所或醫療機構。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第2章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品分類
  • 按指示摘錄
  • 按地區分類

第3章：動態

  • 影響因素
    • 驅動程式
      • 診斷技術的進步
      • 癌症發生率上升
    • 限制
      • 診斷程序和設備成本高昂
      • 發展中地區交通不便
    • 機會
      • 早期檢測和篩檢項目的成長
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的既定領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第5章：癌症診斷市場（按產品）

  • 耗材
    • 抗體
    • 試劑盒和試劑
    • 探針
    • 其他
  • 儀器
    • 病理學儀器
      • 組織處理系統
      • 細胞處理器
      • PCR儀器
      • NGS儀器
      • 微陣列
      • 其他
  • 成像儀器
    • CT系統
    • 超音波系統
    • MRI 系統
    • 乳房X光檢查系統
    • 其他
  • 基於生物標記的
  • 切片器械

第6章：癌症診斷市場（依適應症分類）

  • 乳癌
  • 大腸直腸癌
  • 子宮頸癌
  • 肺癌
  • 攝護腺癌
  • 皮膚癌
  • 血癌
  • 腎癌
  • 肝癌
  • 胰腺癌
  • 卵巢癌
  • 其他

第7章：癌症診斷市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第8章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第9章：公司簡介

  • F. Hoffmann-La Roche Ltd
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 併購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT分析
  • Abbott.
  • Thermo Fisher Scientific Inc.
  • Siemens Healthcare Private Limited
  • GE HealthCare.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Hologic, Inc.
  • Koninklijke Philips NV,
  • BD.
  • QIAGEN

第10章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 11 章：附錄

簡介目錄
Product Code: CD1795

The global cancer diagnostics market reached US$ 21.71 billion in 2024 and is expected to reach US$ 42.64 billion by 2033, growing at a CAGR of 8.7% during the forecast period of 2025-2033.

The global cancer diagnostics market encompasses the industry focused on medical devices, tools, technologies, and services used to detect and diagnose various types of cancer, particularly at early stages. This market includes a wide array of diagnostic solutions, such as imaging methods (e.g., MRI, CT scans, PET scans), molecular and genetic tests (e.g., next-generation sequencing, liquid biopsy), pathology tests, and screening techniques that help identify cancer-related biomarkers.

The primary objective of these diagnostic tools is to provide accurate and timely cancer detection, enabling more effective, personalized treatment options and ultimately improving patient outcomes and survival rates. The market is propelled by the growing prevalence of cancer, ongoing advancements in diagnostic technologies, and increasing demand for early detection and personalized cancer care.

Market Dynamics: Drivers & Restraints

Rising Incidence and Prevalence Of Cancer

The rising incidence and prevalence of cancer are significantly driving the growth of the diagnostics for the cancer market and are expected to drive the market over the forecast period. For instance, according to the Globocon data in 2022, the cancer incidence for males was 10.3 million, while for females, it was 9.7 million. By 2025, the cancer incidence is projected to reach 12.5 million for males and 11.6 million for females. This escalating incidence highlights the urgent need for accessible and cost-effective cancer diagnostics solutions.

The aging global population is contributing to a higher risk of cancer, as older individuals are more susceptible to developing the disease. This demographic shift has resulted in a rise in cancer cases, highlighting the increasing demand for diagnostic tests that can detect cancer at earlier stages, ultimately improving treatment outcomes.

As a result, the rising number of cancer cases directly boosts the demand for cancer diagnostics, leading to a growing market for related products and services. This includes diagnostic tests, imaging systems, and laboratory services that are crucial for identifying and monitoring different types of cancer. These trends create a pressing need for advanced diagnostic technologies, fuel market growth, and underscore the importance of addressing disparities in cancer care globally.

High Costs of Diagnostic Procedures and Equipment

High costs of diagnostic procedures and equipment are a significant barrier to the growth of diagnostics for the cancer market. Several advanced diagnostic tools are essential for the early and accurate detection of cancer, but the high expenses associated with their implementation can create significant challenges. These tools, such as next-generation sequencing (NGS), liquid biopsy, and high-resolution imaging systems, come with a combination of direct and indirect costs that limit their accessibility and widespread use.

According to the researchers, the estimated $43 billion annual cost for initial cancer screening in 2021 is lower than the reported annual cost of cancer treatment in the U.S. during the first 12 months following diagnosis. They emphasize that understanding cancer screening costs and their underlying factors is crucial for informing policy decisions and guiding the development of programs aimed at improving access to recommended cancer screening services.

Advanced diagnostic technologies require a substantial upfront investment. For instance, NGS systems can cost hundreds of thousands of dollars, and high-resolution imaging machines like PET/CT scanners or MRI machines can cost millions. The price of purchasing these machines is a major barrier, especially for smaller hospitals, clinics, or healthcare facilities in low- and middle-income countries.

Segment Analysis

The global cancer diagnostics market is segmented based on product, indication, and region.

Product:

The consumables segment in the product is expected to dominate the global cancer diagnostics market with the highest market share

Consumables in cancer diagnostics encompass the single-use or limited-use materials necessary for conducting various diagnostic tests. These items play a critical role in ensuring accurate, reliable, and efficient cancer detection. These items are critical for every step of the diagnostic process, from sample collection and processing to the execution of complex assays.

Consumables are the backbone of the day-to-day operations in cancer diagnostic laboratories. They ensure that every step of the testing process, from sample collection to final analysis, adheres to rigorous quality standards, ultimately improving early detection, treatment planning, and patient outcomes.

Consumables include antibodies, kits & reagents, probes, and other related tools form the foundation of modern cancer diagnostics. They empower clinicians to perform precise, dependable, and increasingly personalized tests, leading to earlier cancer detection and customized treatment strategies for individual patients.

Furthermore, key players in the industry are making innovative launches that would drive this segment's growth in the market. For instance, in August 2024, Oncosure developed and launched a rapid cancer screening test that can detect all types of cancer using just a single blood draw. This indicates that Oncosure has developed and launched an innovative diagnostic tool that rapidly identifies cancer. These factors have solidified the segment's position in the global cancer diagnostics market.

Geographical Analysis

North America is expected to hold a significant position in the global cancer diagnostics market, with the highest market share

North America is expected to hold the largest market share in the global cancer diagnostics market. North America, particularly the United States, has a high cancer prevalence, which fuels the demand for cancer diagnostics solutions.

According to the National Institutes of Health (NIH) data in May 2024, cancer has a significant impact on society both in the United States and globally. Cancer statistics offer insight into the scope of the disease and reflect its burden on society. In 2024, it is estimated that 2,001,140 new cases of cancer will be diagnosed in the United States, and 611,720 people will succumb to the disease. The escalating incidence of cancer underscores the urgent need for cancer diagnostics solutions that are both accessible and cost-effective.

The field of early cancer screening is in dire need of a revolution. Over the next 30 years, more than 40 million Americans are expected to be diagnosed with late-stage cancer, representing 44% of all new cancer diagnoses in the U.S. In this region, a major number of key players are present, including government initiatives, programs, and product approvals that would drive this market growth.

For instance, in February 2024, the National Institutes of Health (NIH) launched the Cancer Screening Research Network (CSRN) to evaluate and advance emerging technologies for cancer screening. This initiative is part of the broader efforts to support the Biden-Harris administration's Cancer Moonshot initiative, which aims to accelerate progress in cancer research and reduce cancer mortality by making significant advances in early detection and treatment.

Also, in August 2024, the Biden-Harris Administration's ARPA-H (Advanced Research Projects Agency for Health) launched a new program aimed at developing an at-home multi-cancer screening test. This initiative is designed to revolutionize the way we detect cancers, especially those that are difficult to diagnose early.

Similarly, in August 2024, Illumina, Inc. announced that the Food and Drug Administration (FDA) had approved its TruSight Oncology (TSO) Comprehensive test as an in vitro diagnostic (IVD) tool, along with its first two companion diagnostic (CDx) indications. This approval marks a significant advancement in cancer diagnostics, providing a valuable tool for both clinicians and patients. Thus, the above factors are consolidating the region's position as a dominant force in the global cancer diagnostics market.

Competitive Landscape

The major global players in the cancer diagnostics market include F. Hoffmann-La Roche Ltd, Abbott, Thermo Fisher Scientific Inc., Siemens Healthcare Private Limited, GE HealthCare, Illumina, Inc., Bio-Rad Laboratories, Inc., Hologic, Inc., Koninklijke Philips N.V., BD, and QIAGEN, among others.

Key Developments

  • In January 2025, Roche received FDA approval for a companion diagnostic-a test designed to identify patients who are most likely to benefit from a specific treatment. In this case, the test determines whether patients with HER2-ultralow metastatic breast cancer are eligible for treatment with ENHERTU.
  • In September 2024, Roche announced an expansion of its digital pathology platform by integrating over 20 advanced AI algorithms from eight new collaborators. Digital pathology involves scanning traditional glass microscope slides and analyzing them using digital tools, including AI, to improve diagnostic accuracy and efficiency.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global cancer diagnostics market report delivers a detailed analysis with 57 key tables, more than 51 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product
  • 2.4. Snippet by Indication
  • 2.5. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Advancements in Diagnostic Technologies
      • 3.1.1.2. Rising Prevalence of Cancer
    • 3.1.2. Restraints
      • 3.1.2.1. High Costs of Diagnostic Procedures and Equipment
      • 3.1.2.2. Limited Accessibility in Developing Regions
    • 3.1.3. Opportunity
      • 3.1.3.1. Growth in Early Detection and Screening Programs
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Cancer Diagnostics Market, By Product

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
    • 5.1.2. Market Attractiveness Index, By Product
  • 5.2. Consumables*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Antibodies
    • 5.2.4. Kits & Reagents
    • 5.2.5. Probes
    • 5.2.6. Others
  • 5.3. Instruments
    • 5.3.1. Pathology-based Instruments
      • 5.3.1.1. Tissue Processing Systems
      • 5.3.1.2. Cell Processors
      • 5.3.1.3. PCR Instruments
      • 5.3.1.4. NGS Instruments
      • 5.3.1.5. Microarrays
      • 5.3.1.6. Others
  • 5.4. Imaging Instruments
      • 5.4.1.1. CT Systems
      • 5.4.1.2. Ultrasound Systems
      • 5.4.1.3. MRI Systems
      • 5.4.1.4. Mammography Systems
      • 5.4.1.5. Others
  • 5.5. Biomarker-Based
  • 5.6. Biopsy Instruments

6. Cancer Diagnostics Market, By Indication

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 6.1.2. Market Attractiveness Index, By Indication
  • 6.2. Breast Cancer*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Colorectal Cancer
  • 6.4. Cervical Cancer
  • 6.5. Lung Cancer
  • 6.6. Prostate Cancer
  • 6.7. Skin Cancer
  • 6.8. Blood Cancer
  • 6.9. Kidney Cancer
  • 6.10. Liver Cancer
  • 6.11. Pancreatic Cancer
  • 6.12. Ovarian Cancer
  • 6.13. Others

7. Cancer Diagnostics Market, By Regional Market Analysis and Growth Opportunities

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 7.1.2. Market Attractiveness Index, By Region
  • 7.2. North America
    • 7.2.1. Introduction
    • 7.2.2. Key Region-Specific Dynamics
    • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.2.5.1. U.S.
      • 7.2.5.2. Canada
      • 7.2.5.3. Mexico
  • 7.3. Europe
    • 7.3.1. Introduction
    • 7.3.2. Key Region-Specific Dynamics
    • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.3.5.1. Germany
      • 7.3.5.2. U.K.
      • 7.3.5.3. France
      • 7.3.5.4. Spain
      • 7.3.5.5. Italy
      • 7.3.5.6. Rest of Europe
  • 7.4. South America
    • 7.4.1. Introduction
    • 7.4.2. Key Region-Specific Dynamics
    • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.4.5.1. Brazil
      • 7.4.5.2. Argentina
      • 7.4.5.3. Rest of South America
  • 7.5. Asia-Pacific
    • 7.5.1. Introduction
    • 7.5.2. Key Region-Specific Dynamics
    • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.5.5.1. China
      • 7.5.5.2. India
      • 7.5.5.3. Japan
      • 7.5.5.4. South Korea
      • 7.5.5.5. Rest of Asia-Pacific
  • 7.6. Middle East and Africa
    • 7.6.1. Introduction
    • 7.6.2. Key Region-Specific Dynamics
    • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8. Competitive Landscape and Market Positioning

  • 8.1. Competitive Overview and Key Market Players
  • 8.2. Market Share Analysis and Positioning Matrix
  • 8.3. Strategic Partnerships, Mergers & Acquisitions
  • 8.4. Key Developments in Product Portfolios and Innovations
  • 8.5. Company Benchmarking

9. Company Profiles

  • 9.1. F. Hoffmann-La Roche Ltd*
    • 9.1.1. Company Overview
    • 9.1.2. Product Portfolio
      • 9.1.2.1. Product Description
      • 9.1.2.2. Product Key Performance Indicators (KPIs)
      • 9.1.2.3. Historic and Forecasted Product Sales
      • 9.1.2.4. Product Sales Volume
    • 9.1.3. Financial Overview
      • 9.1.3.1. Company Revenue
      • 9.1.3.2. Geographical Revenue Shares
      • 9.1.3.3. Revenue Forecasts
    • 9.1.4. Key Developments
      • 9.1.4.1. Mergers & Acquisitions
      • 9.1.4.2. Key Product Development Activities
      • 9.1.4.3. Regulatory Approvals, etc.
    • 9.1.5. SWOT Analysis
  • 9.2. Abbott.
  • 9.3. Thermo Fisher Scientific Inc.
  • 9.4. Siemens Healthcare Private Limited
  • 9.5. GE HealthCare.
  • 9.6. Illumina, Inc.
  • 9.7. Bio-Rad Laboratories, Inc.
  • 9.8. Hologic, Inc.
  • 9.9. Koninklijke Philips N.V.,
  • 9.10. BD.
  • 9.11. QIAGEN

LIST NOT EXHAUSTIVE

10. Assumptions and Research Methodology

  • 10.1. Data Collection Methods
  • 10.2. Data Triangulation
  • 10.3. Forecasting Techniques
  • 10.4. Data Verification and Validation

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us